Verapamil use in patients with cardiovascular disease: An overview of randomized trials

Clinical Cardiology

Volumn 21, Issue 9, 1998, Pages 633-641

  Pepine, Carl J ^a   Faich, Gerald ^b   Makuch, Robert ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b IBAH   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calcium antagonists; Cardiovascular disease; Meta analysis; Randomized clinical trials

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIDOFLAZINE; NIFEDIPINE; PLACEBO; TRANDOLAPRIL; VERAPAMIL;

ACUTE HEART INFARCTION; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HEART REINFARCTION; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

EID: 0031716183     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960210906     Document Type: Article

References (37)

1. Held PH, Yusuf S, Furberg CD: Calcium channel blockers in acute myocardial infarction and unstable angina: An overview. Br Med J 1989;299:1187-1192
2. Held PH, Yusuf S: Effects of β-blockers and calcium channel blockers in acute myocardial infarction. Eur Heart J 1993;14(suppl F):18-25
3. Held PH, Yusuf S: Calcium antagonists in the treatment of ischemic heart disease: Myocardial infarction. Coron Artery Dis 1994;5: 21-26
4. Yusuf S, Held PH, Furberg CD: Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol 1991;67:1295-1297
5. Yusuf S, Lessem J, Jha P, Lonn E: Primary and secondary prevention of myocardial infarction and strokes: An update of randomly allocated, controlled trials. J Hypertens 1993;11(suppl 4):S61-S73
6. Furberg CD: Secondary prevention trials after myocardial infarction. J Cardiovasc Pharmacol 1988;12(suppl 1):S83-S87
7. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, Wagner EH, Furberg CD: The risk of myocardial infarction associated with antihypertensive drug therapies. J Am Med Assoc 1995; 274:620-625
8. Buring JE, Glynn RJ, Hennekens CH: Calcium channel blockers and myocardial infarction. A hypothesis formulated but not yet tested. J Am Med Assoc 1995;274:654-655
9. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH: Blood pressure, stroke, and coronary disease. Lancet 1990;335:827-838
10. Mantel N, Haenszel W: Statistical analysis of the analysis of data from retrospective studies of disease. JNCI 1959;22:719-748
11. Hansen JF: Review of postinfarct treatment with verapamil: Combined experience of early and late intervention studies with verapamil in patients with acute myocardial infarction. Cardiovasc Drugs Ther 1994;8(suppl 3):543-547
12. Hansen JF, Sigurd B, Mellemgaard K, Lyngbye J: Verapamil in acute myocardial infarction. Dan Med Bull 1980;27:105-109
13. Hansen JF, Hagerup L, Sigurd B, Pedersen F, Mellemgaard K, Pedersen-Bjergaard O, Mortensen LS, for the Danish Verapamil Infarction Trial (DAVIT) Study Group: Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone. Am J Cardiol 1997;79: 738-741
14. Rehnqvist N, Hjemdahl P, Billing E, Bjorkander I, Eriksson SV, Forslund L, Held C, Nasman P, Wallen NH: Effects of metoprolol vs. verapamil in patients with stable angina pectoris: The angina prognosis study in Stockholm (APSIS). Eur Heart J 1996;17:76-81
15. Crea F, Deanfield J, Crean P, Sharon M, Davies G, Maseri A: Effects of verapamil in preventing early post-infarction angina and reinfarction. Am J Cardiol 1985;55:900-904
16. The Danish Study Group on Verapamil in Myocardial Infarction: Verapamil in acute myocardial infarction. Eur Heart J 1984;5: 516-528
17. Rengo F, Carbonin P, Pahor M, DeCaprio L, Bernabei R, Ferrara N, Carosella L, Acanfora D, Parlati S, Vitale D: A controlled trial of verapamil in patients after acute myocardial infarction: Results of the calcium antagonist reinfarction Italian study (CRIS). Am J Cardiol 1996;77:365-369
18. Bussman WD, Seher W, Gruengras M: Reduction of creatine kinase and creatine kinase-MB indexes of infarct size by intravenous verapamil. Am J Cardiol 1984;54:1224-1230
19. The Danish Study Group on Verapamil in Myocardial Infarction: Effect of verapamil on mortality and major events after acute myocardial infarction. The Danish Verapamil Infarction Trial II (DAVIT-II). Am J Cardiol 1990;66:779-785
20. Mehta J, Pepine CJ, Day M, Guerrero JR, Conti CR: Short-term efficacy of oral verapamil in rest angina. A double-blind placebo controlled trial in CCU patients. Am J Med 1981;71:977-982
21. Hoberg E, Dietz R, Frees U, Katus HA, Rauch B, Schomig A, Schuler G, Schwarz F, Tillmanns H, Niebauer J, Kübler W: Verapamil treatment after coronary angioplasty in patients at high risk of recurrent stenosis. Br Heart J 1994;71:254-260
22. Klein MD, Weiner DA, Kellett MA Jr: Regular formation and sustained-release verapamil therapy in normotension and in mild to moderate hypertension. Am J Cardiol 1986;57:69D-73D
23. Belz GG, Spies G: Controlled study on the treatment of hypertension with verapamil in retard form. Z Kardiol 1985;74:453-459
24. Cubeddu LX, Aranda J, Singh B, Klein M, Brachfeld J, Freis E, Roman J, Eades T: A comparison of verapamil and propranolol for the initial treatment of hypertension: Racial differences in response. J Am Med Assoc 1986;256:2214-2221
25. Halperin AK, Gross KM, Rogers JF, Cubeddu LX: Verapamil and propranolol in essential hypertension. Clin Pharmacol Ther 1984; 36:750-758
26. Agabiti-Rosei E, Muiesan ML, Romanelli G, Beschi M, Castellano M, Muiesan G: Reversal of cardiac hypertrophy by long-term treatment with calcium antagonists in hypertensive patients. J Cardiovasc Pharmacol 1988;12(suppl 6):S75-S78
27. Packer M: Pathophysiological mechanisms underlying the adverse effect of calcium channel-blocking drugs in patients with chronic heart failure. Circulation 1989;80(6 suppl):IV59-IV67
28. The Danish Study Group on Verapamil in Myocardial Infarction: Secondary prevention with verapamil after myocardial infarction. Am J Cardiol 1990;66:331-401
29. Hansen JF, Tingsted L, Rasmussen V, Madsen JK, Jespersen CM: Verapamil and angiotensin-converting enzyme inhibitors in patients with coronary artery disease and reduced left ventricular ejection fraction. Am J Cardiol 1996;77:16D-21D
30. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335: 1107-1114
31. Boden WE, Ziesche S, Carson PE, Conrad CH, Syat D, Cohn JN: Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): Felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. Am J Cardiol 1996;77:1078-1082
32. Figulla HR, Gietzen F, Zeymer U, Raiber M, Hegselmann J, Soballa R, Hilgers R: Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Results of the Diltiazem in Dilated Cardiomyopathy Trial. Circulation 1996;94:346-352
33. Jespersen CM, Hansen JF, for the Danish Study Group on Verapamil in Myocardial Infarction: Effect of verapamil on reinfarction and cardiovascular events in patients with arterial hypertension included in the Danish Verapamil Infarction Trial II. J Hum Hypertens 1994;8:85-88
34. Hjemdahl P, Eriksson SV, Held C, Rehnqvist N: Prognosis of patients with stable angina pectoris on antianginal drug therapy. Am J Cardiol 1996;77:6D-15D
35. Yusuf S, Wittes J, Probstfield J, Tyroler HA: Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. J Am Med Assoc 1991;266:93-98
36. Rosei EA, Dal Palu C, Leonetti G, Magnani B, Pessina A, Zanchetti A: Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. VHAS Investigators. J Hypertens 1997; 15(11):1337-1344
37. Hennekens CH, Albert CM, Godfried SL, Gaziano JM, Buring JE: Adjunctive drug therapy of acute myocardial infarction - evidence from clinical trials. N Engl J Med 1996;335:1660-1667